News

Endobetix was mentioned in an article (translated excerpt below) in the Hebrew press which reported on the recent MIXiii Innovation Conference | Biomed held in Tel Aviv in May, 2014.

Diverting Bile Aids Diabetics

“Endobetix’s goal is to divert the bile elsewhere in the intestine, without the need for complete gastric bypass surgery, which presents risks to the patient.”

“Background: Chen Porat is a serial entrepreneur in the medical device industry and intimately familiar with the field of obesity and diabetes treatment from his work at the food supplement company Nutrinia. Porat knew Pierre Sharvit, who founded the medical device company Pro-IV. Together, they founded the company Endobetix.”

Gastric bypass surgery, which has been used to treat diabetes indirectly by treating obesity, has proved to lower sugar levels in the blood and improve blood sugar levels on the first day of the surgery, before the patient has shed a kilogram of weight.

It appears that bariatric surgery positively affects diabetes, regardless of weight loss. In recent years this mechanism has been investigated and other researchers have argued that the secret lies in the bile. Recently, the prestigious journal Nature published an article about this.

Endobetix's goal is to divert the bile elsewhere in the intestine, without performing full gastric bypass surgery, which has risks and limitations for the patient. "The design of the product was a challenge, because the digestive system is very aggressive. Its job is to dispel anything that is foreign by exerting strong muscular force," said Porat.

Ultimately, the company built a kind of funnel that holds the bile liquid and transfers it via a tube through the stomach and the duodenum - while keeping the bile isolated from the contents of the stomach, duodenum and colon - until it can be released in the last part of the intestine.

"The beauty of this treatment is that does not require any commitment from the patient - compared with other treatments for diabetes which require a huge everyday commitment from patients - except to agree and show up for surgery. In fact it is not surgery, but a tiny endoscopic minimally - invasive procedure, requiring no abdominal opening, “said Porat.

The above are translated excerpts from a Hebrew article in Israel's business daily Globes.

For the full article in Hebrew>>


Battling Diabetes

May 2014

Diabetes was one of the issues highlighted at the Biomed Innovation Conference and various solutions were presented by many companies in the field. Type 2 diabetes is a disease which is on the increase in both in the developed and the developing world. The number of people with diabetes worldwide was estimated in 2000 at more than 200 million people, and is expected to reach to 350 million by 2030. Currently available therapies for diabetes include drug therapy and bariatric surgery (gastric bypass). Bariatric surgery is specifically designed to resolve the problem of obesity, but also answers the problem of diabetes. Endobetix, developed a novel way to stop the development of diabetes, by inserting a non-invasive implant that mimics the effects of bariatric surgery, without the actual surgical procedure.

"We realized that most of the change is not due to the operation itself, but that the bile digests the food in a different place," explains Endobetix CEO, Chen Porat. ”Therefore the implant mimics the consequences of bariatric surgery, by causing the bile to move to another place - thereby simulating the effects of bariatric surgery and solving the problem of diabetes -- without invasive surgery."

For the full article in Hebrew>>


All Rights reserved. Endobetix Ltd.